Treatment of autosomal dominant hypocalcemia Type 1 with the calcilytic NPSP795 (SHP635) by Scott Roberts, Mary et al.
Treatment of Autosomal Dominant Hypocalcemia Type 1 with the Calcilytic NPSP795 21 
(SHP635) 22 
Mary Scott Roberts1, Rachel I. Gafni1, Beth Brillante1, Lori C. Guthrie1, Jamie Streit1, David 23 
Gash2, Jeff Gelb2, Eva Krusinska2, Sarah C. Brennan3,4, Martin Schepelmann3,5, Daniela 24 
Riccardi3, Mohd Ezuan Bin Khayat6,7, Donald T. Ward5, Edward F. Nemeth8, Ralf Rosskamp2, 25 
and Michael T. Collins1 26 
1Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and 27 
Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA  28 
2NPS Pharmaceuticals, Inc., Bedminster, NJ  29 
3School of Biosciences, Cardiff University, Cardiff, UK 30 
4School of Life and Environmental Science, University of Sydney, NSW, Australia 31 
5Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, AT 32 
6Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK 33 
7Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, 34 
Malaysia 35 
8MetisMedica, Toronto, ON, Canada 36 
 37 
Corresponding author and person to whom reprint requests should be addressed:  38 
Michael T. Collins, MD 39 
Skeletal Disorders and Mineral Homeostasis Section, NIDCR 40 
National Institutes of Health 41 
Building 30, Room 228 42 
30 Convent Dr. MSC 4320 43 
Bethesda, MD 20892-4320 44 
301-496-4913 (tel) 45 
Mc247k@nih.gov 46 
 47 
Supplemental data is included with the manuscript. 48 
49 
Disclosures:  50 
The NIDCR Investigators (MSR, BB, LCG, RIG, JS, and MTC) received non-salary financial 51 
support from NPS Pharmaceuticals to conduct the research described herein and financial 52 
support from Shire for research investigating pharmaceutical agents not discussed in this work. 53 
SCB, MS, DR, MBK, and DTW received financial support from NPS Pharmaceuticals to 54 
conduct research described herein.  DG, JG, EK, and RR were employees of NPS 55 
Pharmaceuticals when this research was conducted.  MSR became an employee of Ultragenyx 56 
Pharmaceuticals in September 2017, after work on this project was completed.  57 
ABSTRACT  58 
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused 59 
by heterozygous, gain-of-function mutations of the calcium-sensing receptor gene (CAR). 60 
Individuals are hypocalcemic with inappropriately low parathyroid hormone (PTH) secretion and 61 
relative hypercalciuria. Calcilytics are negative allosteric modulators of the extracellular calcium 62 
receptor (CaR) and therefore may have therapeutic benefits in ADH1.  Five adults with ADH1 63 
due to 4 distinct CAR mutations received escalating doses of the calcilytic compound NPSP795 64 
(SHP635) on 3 consecutive days.  Pharmacokinetics, pharmacodynamics, efficacy, and safety 65 
were assessed. Parallel in vitro testing with subject CaR mutations assessed the effects of 66 
NPSP795 on cytoplasmic calcium concentrations (Ca2+i), and ERK and p38MAPK 67 
phosphorylation. These effects were correlated with clinical responses to administration of 68 
NPSP795.  NPSP795 increased plasma PTH levels in a concentration-dependent manner up to 69 
129% above baseline (p=0.013) at the highest exposure levels.  Fractional excretion of calcium 70 
(FECa) trended down but not significantly so. Blood ionized calcium levels remained stable 71 
during NPSP795 infusion despite fasting, no calcitriol and little calcium supplementation. 72 
NPSP795 was generally safe and well-tolerated. There was significant variability in response 73 
clinically across genotypes. In vitro, all mutant CaRs were half-maximally activated (EC50) at 74 
lower concentrations of extracellular calcium (Ca2+o) compared to wild type (WT) CaR; 75 
NPSP795 exposure increased the EC50 for all CaR activity readouts. However, the in vitro 76 
responses to NPSP795 did not correlate with any clinical parameters.  NPSP795 increased 77 
plasma PTH levels in subjects with ADH1 in a dose-dependent manner, and thus, serves as 78 
proof-of-concept that calcilytics could be an effective treatment for ADH1.  Albeit all mutations 79 
appear to be activating at the CaR, in vitro observations were not predictive of the in vivo 80 
phenotype, or the response to calcilytics, suggesting that other parameters impact the response to 81 
the drug.  82 
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INTRODUCTION 93 
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare genetic disorder of mineral 94 
homeostasis (OMIM 601198) caused by gain-of-function mutations of the calcium-sensing 95 
receptor gene (CAR) (3q13.3-q21.1).(1,2)  The extracellular calcium receptor (CaR) is a G-96 
protein-coupled receptor for which extracellular calcium (Ca2+o) is the primary physiological 97 
ligand, and it plays the major role in regulating systemic calcium homeostasis.(3-5)  Gain-of-98 
function mutations in the G-protein subunit α11(Gα11) protein (GNA11) (19p13.3) downstream 99 
of CaR have also been identified as causative for autosomal dominant hypocalcemia type 2 100 
(ADH2) (OMIM #615361).(6-8)   101 
CaRs are prominently expressed in parathyroid glands and the kidney, specifically in the 102 
thick ascending limb of the loop of Henle, distal tubules, and collecting ducts, where they 103 
regulate parathyroid hormone (PTH) secretion and calcium reabsorption, respectively.(3,9) 104 
Increases in Ca2+o activate the receptor and trigger downstream signaling leading to suppressed 105 
PTH secretion and renal calcium reabsorption.  Thus, heterozygous mutations in ADH1 decrease 106 
CaR half-maximal activation (EC50) to Ca2+o such that PTH secretion is decreased and renal 107 
calcium excretion increased. Decreased PTH leads to hypocalcemia and may result in symptoms 108 
that include peripheral and oral paresthesias, muscle cramps, tetany and seizures. Increased renal 109 
calcium excretion results in development of nephrocalcinosis, nephrolithiasis, and impaired renal 110 
function in some patients.(10)  111 
Conventional therapy for ADH1 patients who require treatment includes calcium and 112 
vitamin D analogs; however, the rise in blood calcium exacerbates the hypercalciuria, placing 113 
patients at increased risk of renal complications. (10) Thus, current practice for those on treatment 114 
is to maintain calcium levels near or slightly below the lower limit of normal. However, some 115 
patients continue to experience neuromuscular and cognitive symptoms of hypocalcemia and 116 
sustain renal complications. Because of the inadequacy of conventional treatment, and its 117 
potential for morbidities, precision therapy that could normalize both blood calcium and urinary 118 
calcium excretion in ADH1 patients who require treatment would represent a significant 119 
improvement.  120 
Calcilytics, CaR negative allosteric modulators, increase PTH secretion and decrease 121 
renal calcium excretion. NPSP795 (SHP635), one such calcilytic, and its structurally-related 122 
compounds NPSP790 and NPS2143 were shown to increase PTH in rats, dogs, and monkeys (11), 123 
and in addition, were shown to increase blood calcium as well as decrease renal calcium 124 
excretion in PTH infusion-clamped rats (12), suggesting a potential benefit in ADH1.  Moreover, 125 
the calcilytic NPS2143 has been shown to reduce signaling responses of cells with gain-of-126 
function CAR mutations causative of ADH1 (13), and increased blood calcium after a single 127 
intraperitoneal injection in a mouse model of ADH1 (14), the Nuf mouse. (15)  Similarly, NPS2143 128 
reduced mutant Val62 Gα11 signaling responses in vitro and led to an increase in plasma PTH 129 
and calcium concentrations in two animal models of ADH2. (16,17)  The calcilytic JTT-305 (MK-130 
5442) resulted in increased serum calcium and decreased urinary calcium by stimulating 131 
endogenous PTH secretion and prevented renal calcification in knock-in mice with human CAR 132 
(C129S) and CAR (A843E) mutations. (18)   133 
We thus hypothesized that the calcilytic NPSP795 may be effective in treating ADH1, 134 
and that by assessing the effect of NPSP795 on subject mutations in vitro and comparing the 135 
results to clinical findings we could gain insight into genotype/phenotype correlations as well as 136 
potentially predict how patients with specific mutations may respond to NPSP795.  The present 137 
proof-of-concept study was designed to assess the pharmacodynamics (PD), pharmacokinetics 138 
(PK), efficacy, as assessed by change in PTH and PTH AUC, and safety of NPSP795 in adult 139 
patients with ADH1. In vitro studies assessed the potency of Ca2+o on CaR-induced intracellular   140 
Ca2+ (Ca2+i) mobilization, and ERK and p38MAPK phosphorylation in the patient mutations, and 141 
the effect of NPSP795 on these parameters and the correlation between these parameters and 142 
each patients’ clinical response, as assessed by PTH AUC. 143 
 144 
METHODS 145 
 Study participants.  Adults with a previously established clinical diagnosis of ADH1, 146 
confirmed by CAR gene mutation, BMI  18.5 to < 39 kg/m2, and 25-hydroxy-vitamin D > 25 147 
ng/mL were enrolled in this study from June 2014 to April 2015.  Key exclusion criteria were 148 
treatment with PTH 1-84 or 1-34 within the previous 6 months; hypocalcemia requiring more 149 
than 6 IV calcium infusions per year; hypocalcemic seizures within the past 3 months; 150 
glomerular filtration rate (GFR) < 25 mL/minute/1.73 m2; abnormal hepatic, hematologic, and/or 151 
clotting function; 12-lead resting electrocardiogram (ECG) with clinically significant 152 
abnormalities; concomitant medications with potential to interfere with NPSP795 metabolism; 153 
and history of thyroid or parathyroid surgery.   154 
 Study design.  This was an open-label, non-randomized, single-center, intra-subject dose-155 
escalating phase IIb study in adults with ADH1.  The study medication, NPSP795, a calcilytic, 156 
was provided by NPS Pharmaceuticals, Inc.  157 
 After screening and baseline assessments, subjects were admitted to the National 158 
Institutes of Health (NIH) Clinical Center for a 5-day, 4-night admission.  Subjects who were 159 
treated with calcitriol discontinued the medication 2 days prior to the start of NPSP795.  Home 160 
calcium supplements were administered up until the day of the first NPSP795 infusion.  161 
Thereafter, calcium supplementation was administered based on clinical symptoms of 162 
hypocalcemia as deemed necessary by the investigators.  Subjects fasted from midnight until 4 163 
hours after each infusion start.  When not fasting, they consumed approximately 1000 mg/day of 164 
calcium from dietary sources throughout the study, but the diet was otherwise not standardized.  165 
The ionized calcium level was measured prior to each NPSP795 infusion and had to be 0.75 to 166 
1.25 mmol/L (3-5 mg/dL) to start the infusion. 167 
 Subjects received 5 mg/10min NPSP795 via intravenous infusion on Day 1 with a plan to 168 
repeat the same dose if the ionized calcium was  1.12 mmol/L or the PTH level was > than the 169 
upper limit of normal (65 pg/mL).  NPSP795 was chosen as the compound for this study because 170 
it was the most potent calcilytic that was available from the pharmaceutical collaborator.  171 
Because this was the first study to assess the effects of this class of drugs in ADH1, NPSP795 172 
was administered intravenously in order to more rigorously control blood concentrations of the 173 
drug.  The starting dose was selected because it was tested in previous healthy volunteer studies 174 
(NPSP7975 = SB-423562), was well-tolerated with no safety concerns and resulted in an 175 
increase in serum PTH (11). If there was no increase in ionized calcium or PTH, the dose of 176 
NPSP795 was increased the following day.  Every 1 hour during the testing period, an 177 
investigator assessed tolerability of the infusion and monitored the ionized calcium levels and 178 
blood PTH levels.  Because no subjects met the ionized calcium or PTH criteria to repeat a dose 179 
of NPSP795, they all received 15 mg/3.5h on Day 2 and 30 mg/3.5 h on Day 3 via intravenous 180 
infusion.  These doses were determined using the indirect pharmacodynamic response model 181 
generated from healthy volunteer data in combination with the No Observed Adverse Effect 182 
Level of the drug in pre-clinical toxicology studies in non-human primates.  Subjects underwent 183 
serial sampling via intravenous catheter to assess PK, PD, and safety parameters starting at 184 
baseline prior to each drug infusion.  Subjects resumed home medications the morning following 185 
the final infusion of NPSP795 and were discharged home to the care of their local physician.  186 
Study objectives and assessments.  The primary objectives of the study were to assess the 187 
safety and tolerability of NPSP795 when administered as multiple, dose-escalating i.v. infusions 188 
and to assess the PD effects and preliminary efficacy on change from baseline ionized calcium, 189 
blood and urinary calcium, and PTH.  Renal ultrasounds were performed at the outpatient 190 
screening visit. 191 
Safety assessments included evaluation for adverse events, physical examinations, ECGs, 192 
vital signs, bedside ionized calcium measurements, and standard clinical laboratory evaluations. 193 
Safety and tolerability were monitored continuously during the study while subjects were 194 
admitted to the NIH Clinical Center.  A telephone follow-up safety assessment was performed 195 
approximately 14 days following discharge.   196 
 Sample collection.  To measure relevant PK/PD parameters such as NPSP795 drug 197 
concentrations, ionized calcium, blood and urine calcium, PTH, blood and urine phosphate, 198 
blood and urine creatinine, we collected samples from subjects at various time points depending 199 
on the dose of NPSP795.  For NPSP795 5 mg/10min dose, blood sampling for PK and PTH 200 
determinations were performed at baseline, every 5 minutes for 15 minutes, every 15 minutes for 201 
30 minutes, every 30 minutes until hour 4, and at 8 hours. Ionized calcium was measured at 202 
baseline, every 15 minutes for the first 2 hours and every 30 minutes thereafter until hour 4.  For 203 
the 3.5h NPSP795 infusions, PK and PTH determinations were performed at baseline, every 15 204 
minutes for 30 minutes, every 30 minutes until hour 4, and at hours 5 and 5.5; ionized calcium 205 
was measured at baseline, every 15 minutes for the first 2 hours and every 30 minutes thereafter 206 
until hour 4, and at hours 5 and 8 thereafter.  Blood and spot urine sampling for determination of 207 
additional PD and other parameters was performed at baseline, 1, 2, 3, 4, 8, and 12 hours for all 208 
NPSP795 doses.  209 
Routine blood and urine chemistries and complete blood count (CBC) were performed at 210 
the NIH Clinical Center Department of Laboratory Medicine.  iPTH was determined via 211 
electrochemiluminescence immunoassay (Roche Cobas e601 analyzer; NIH, Bethesda, MD, 212 
USA), and 25-hydroxy-vitamin D was measured by chemiluminescence immunoassay (NIH, 213 
Bethesda, MD, USA).  Ionized calcium measurements were performed at the subject’s bedside 214 
using the Radiometer ABL80 FLEX CO-OX blood gas analyzer (Radiometer America, Brea, 215 
CA, USA).  NPSP795 blood concentrations were determined via a liquid chromatography/ 216 
tandem mass spectrometry assay with a lower limit of quantitation of 10.0 ng/mL that was 217 
validated in accordance with the FDA Guidance for Industry. Estimated GFR was calculated 218 
using the CKD-EPI equation.  FECa was determined using the following calculation: (Urine-219 
calcium*Plasma creatinine) / (Urine-creatinine*Plasma-total calcium). 220 
Study approval. This study was conducted in accordance with the ethical principles of the 221 
Declaration of Helsinki, and it received approval from the Institutional Review Board of the 222 
National Institute of Diabetes and Digestive and Kidney Diseases, NIH.  All participants 223 
provided written informed consent before participating in any study procedures.  The study was 224 
registered with ClinicalTrials.gov (NCT02204579).    225 
In vitro studies: Generation of stable cell lines expressing WT or mutant CARs.  Site-226 
directed mutagenesis was performed using the Stratagene QuikChange™ II kit according to the 227 
manufacturer's instructions. Briefly, a pair of complementary primers of 25–35 bases was 228 
designed for each mutagenesis reaction with the mutation placed at the middle of the primers 229 
(Supplemental Table 1). The template, a cassette version of human CaR in pcDNA3.1(+) was 230 
amplified using Pfu II DNA polymerase with these primers for 18 cycles in a DNA thermal 231 
cycler. After digestion of the template DNA with DpnI the amplified mutant DNA was 232 
transformed into DH5α Escherichia coli. The incorporation of the desired mutations and absence 233 
of other mutations were confirmed by automated DNA sequencing (Eurofin MWG). Successful 234 
mutants and wt CaR were excised using restriction sites either side of the receptor (HindII/ApaI) 235 
in the multiple cloning site, before being ligated into a pcDNA5/FRT plasmid for generation of 236 
stable cell lines using the Flp-In system (ThermoFisher).  237 
Generation of cell lines. Stably expressing cell lines were developed using the Flp-In 238 
system (ThermoFisher) for generating constitutive expression cells lines. Commercially available 239 
Flp-In-293 cell lines from ThermoFisher are derived from HEK293 cells and stably express the 240 
pFRT/lacZeo plasmid containing an integrated Flp Recombinase Target (FRT) site.  Flp-In-293 241 
cells were maintained in 25-cm2 culture flasks and transfected with both pcDNA5/FRT/CaR 242 
(containing either WT or one of the ADH mutants) and pOG44 plasmid at a 9:1 ratio using 243 
Lipofectamine 2000TM according to the manufacturer’s instructions. Transfection of pOG44 244 
leads to expression of Flp Recombinase and catalyses a homologous recombination effect 245 
between the FRT sites in pcDNA5/FRT/CaR and Flp-In-293 cells. Cells were selected over 2 - 3 246 
weeks through media containing 150 ng/mL hygromycin. Resistant cells were then screened for 247 
activity in response to Ca2+o. 248 
Receptor expression.  As part of the initial screening process the effect of ADH mutations 249 
on cell surface expression using transiently transfected FLAG-tagged WT or ADH mutant 250 
constructs was examined. This version of the CaR has a FLAG-tag between residues 371 and 251 
372 in a loop tolerant of in-frame insertions. (19)  252 
Cell surface expression by ELISA.  Quantification of total and cell surface expression was 253 
completed using an ELISA based assay that has been previously published. (20)  HEK293 cells 254 
were transfected with WT or one of the 5 ADH Flag-tagged CaR constructs using 255 
Lipofectamine2000TM according to the manufacturer’s instructions. After ~ 24 hours transfected 256 
HEK293 cells were cultured into Poly-D-Lysine (Sigma) coated 96 well plates. Once cell 257 
reached an approximate density of 100% cells were washed once with TBS-T (0.05 M Tris, 0.15 258 
M CaCl, 0.05% (w/v) Tween-20, pH 7.4) and fixed for 15 mins on ice with either 4% 259 
paraformaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 260 
7.4) to determine surface expression or methanol to determine total expression. After washing 261 
once with TBS-T, cells were blocked for 1 h at room temperature in 1% (w/v) skim milk in TBS-262 
T, before being incubated with 1:1000 monoclonal FLAG M2 horse-radish peroxidase (HRP)-263 
conjugated antibody (Sigma-Aldrich) in blocking solution for 1 h at room temperature. After 264 
incubation with the antibody, cells were washed three times with TBS-T before being incubated 265 
with a HRP substrate (3,3’5,5’ tetramethylbenzidence (TMB) liquid substrate solution) for 30 266 
min in the dark. Enzyme reaction was stopped by adding equal volumes of 1 M HCl. Supernatant 267 
samples were transferred to a new plate and A450 values were obtain through a plate reader. 268 
Measurements of Ca2+i in populations of cells using a plate reader.  Cells were plated in 269 
96 well plates and grown to confluence before being loaded with 2 µM Fluo-4 for 30 min. Using 270 
a Fluoroskan Ascent plate reader (ThermoFisher Scientific), an initial baseline reading of ten 271 
measurements (at a calcium concentration of 0.2 mM) was taken to determine the 0 sec value.  272 
Calcium solutions which increased calcium concentration to 0.2 - 8 mM, in the presence and 273 
absence of 1 µM NPSP795 or vehicle control (0.01% DMSO), were dispensed into a single well 274 
and emission at 538 nm for each well was then followed for 30 s (1 reading every 5 seconds). 275 
Dose response curves were generated from the peak fluorescence upon the addition of the 276 
calcium solution and corrected for the initial baseline measurement. Peak fluorescence was then 277 
normalized to a 10 mM calcium + 2 µM ionomycin response to enable comparison between 278 
different plates. 279 
Measurement of ERK and p38MAPK Phosphorylation.  These assays were carried out as 280 
described elsewhere. (21)  Briefly, cells were incubated for 10-mins in either Experimental Buffer 281 
(0.5mM Ca2+o) alone or in buffer supplemented with either a) various concentrations of Ca2+o (2 282 
- 10mM), or b) various concentrations of NPSP795 (1-1000nM; equal DMSO concentration in 283 
all samples) in the presence of either 2.4 mM Ca2+o (ADH mutants) or 3.4 mM Ca2+o (Wild-284 
type); these Ca2+o being close to ~EC80 values for these receptors (with regards to ERK 285 
activation). Where [CaCl2] was increased, [NaCl] was reduced accordingly to normalize ionic 286 
strength. Where NPSP795 was used, cells were pre-exposed to the calcilytic for 30-secs before 287 
application of the high Ca2+o/NPSP795 co-treatment.  The cell lysate supernatant was stored at -288 
80°C until use, whereupon an aliquot was mixed with 5X Laemmli buffer and boiled for 3-min 289 
prior to immunoblotting (40-60 l sample/lane) using the phospho-specific anti-ERK antibody or 290 
anti-p38MAPK antibody (1:5000; Cell Signaling). Protein equivalency of the samples was 291 
demonstrated initially by Ponceau staining the blot (prior to blocking) and then by stripping and 292 
reprobing with either total anti-ERK or anti-β-actin antibodies. Relative immunoreactivity was 293 
determined by densitometry. 294 
Statistics.  The statistical analyses for the clinical research study were performed using 295 
SAS® software version 9. A mixed model repeat measures analysis with unstructured covariance 296 
matrix and Tukey adjustment was used.  A p value of less than 0.05 was considered statistically 297 
significant. Statistical analyses performed for the in vitro studies using GraphPad Prism v5 298 
included one-way ANOVA and Dunnett’s post-test when comparing log EC50 of CaR mutants to 299 
that of WT.  Unpaired two-tailed Student’s t-tests were used to assess differences between log 300 
EC50 of CaRs in the presence or absence of NPSP795.  Statistical analyses performed to assess 301 
correlations between in vitro and clinical findings included linear regression analysis using 302 
GraphPad Prism v7.   303 
 304 
RESULTS  305 
 Subject characteristics.  Of the 9 patients screened, 8 were eligible, and 5 subjects with a 306 
mean age of 39.8 years (range 23-55) and mean BMI of 32.8 kg/m2 (range 29.4-37.2) completed 307 
the study (Supplemental Figure 1).  Baseline demographics, disease characteristics, and CAR 308 
genotype of subjects enrolled are summarized in Table 1.  All subjects had hypocalcemia, 309 
inappropriately low PTH levels, and had been diagnosed in childhood. Four subjects presented 310 
with hypocalcemic seizures, and 1 subject was tested for hypocalcemia after her mother was 311 
diagnosed with ADH1. Subjects 1 and 4 were first-degree cousins and shared the same mutation, 312 
A840V.  Subject 5 was found to have a novel CAR mutation, E228A.  Four subjects had low 313 
GFR (< 90 mL/min/1.73m2), and 3 subjects had evidence of nephrocalcinosis/nephrolithiasis on 314 
renal ultrasound at baseline.  315 
 Efficacy outcomes. Subjects received 5 mg/10min NPSP795 on Day 1 with a plan to 316 
repeat the same dose if the ionized calcium was  1.12 mmol/L or the PTH level was > than the 317 
upper limit of normal (65 pg/mL).  Because no subjects met the ionized calcium or PTH criteria 318 
to repeat a dose of NPSP795, all subjects received 15 mg/3.5h on Day 2 and 30 mg/3.5 h on Day 319 
3 (Figure 1).  Infusions of NPSP795 resulted in significant increases in blood levels of NPSP795 320 
that were sustained during the infusion period (Figure 2A-C). NPSP795 resulted in a dose- and 321 
concentration-dependent increase in percent change in PTH from baseline, the primary endpoint, 322 
(Figure 2 D-F), that was paralleled by changes in PTH blood levels (Figure 2G-I).  The 323 
maximum mean percent change ( 1SD) in PTH was 128.6% (139%) at 15min following 5 324 
mg/10min dose of NPSP795 (p=0.048), 49% (47%) at 210min following 15 mg/3.5h dose 325 
(p=0.149), and 121% (91%) at 210 min following the 30 mg/3.5h dose (p=0.013) (Figure 2D-326 
F).  The peak mean PTH ( 1SD) was 17.4 pg/mL ( 16) at 15min following 5 mg/10min dose 327 
of NPSP795, 13.7 pg/mL ( 5.9) at 210 min following 15 mg/35h dose, and 21 pg/mL ( 14) at 328 
210min following 30 mg/3.5h dose (Figure 2G-I).  329 
 While fractional excretion of calcium (FECa) was decreased at the higher exposures of 330 
NPSP795, the changes were not statistically significant. The mean (±1SD) maximum decrease in 331 
the FECa occurred during the 15 mg/3.5h (maximum -36% ( 27%) at 120min) and 30 mg/3.5h 332 
(maximum of -43% ( 25%) at 120min) doses (Figure 2J-L).     333 
 The changes in PTH and FECa were not sufficient to result in an increase in blood 334 
calcium levels (Figure 2M-O).  Of note, prescribed calcitriol was discontinued 2 days prior to 335 
study start, calcium supplements were discontinued at least 12 hours prior to study start, and 336 
subjects were fasted for the first four hours of dosing and serial sampling.  Subjects received 337 
between 250-1200 mg of elemental calcium supplementation in the evening.  Two subjects 338 
required rescue calcium for symptoms of hypocalcemia including paresthesias and muscle 339 
cramping that totaled 600 and 1,800 mg of elemental calcium (Supplemental Table 2). Thus, 340 
while ionized calcium levels did not rise in response to NPSP795, they remained stable and did 341 
not decline during NPSP795 administration despite fasting and withholding of calcitriol, 342 
consistent with an effect of NPSP795 infusion on maintaining blood calcium levels. 343 
Safety.  NPSP795 infusions were generally well-tolerated.  In total, 1 serious adverse event and 2 344 
adverse events (AEs) were reported by 3 subjects during the study.  Subject 1, who was obese 345 
and had a family history of cholelithiasis, developed symptomatic cholelithiasis on the morning 346 
of day 4 after receiving the 3 doses of NPSP795.  The symptoms resolved, and he was 347 
discharged home to the care of his primary physician.  However, symptoms returned upon 348 
discharge, and the subject underwent a laparoscopic cholecystectomy.  The subject did well post-349 
operatively without additional adverse events.  Considering the timing of the symptoms in 350 
relation to NPSP795 dosing, the investigators concluded that the SAE was unlike ly to be related 351 
to the study drug.  The other two AEs, facial swelling and bilateral nipple sensitivity, which 352 
occurred 72 and 48 hours after the last dose of study drug, respectively, were deemed unrelated 353 
to NPSP795 and resolved without incident.  No deaths were reported during the study or follow-354 
up period.  The study was discontinued after data from 5 subjects revealed the short-acting nature 355 
of NPSP795 and lack of effect on blood ionized calcium.  356 
Response by genotype.  Despite similar blood concentrations of NPSP795 (Figure 3B), 357 
there was wide variability in the response to this calcilytic across genotypes as assessed by PTH 358 
AUC (Figure 3A).  This is particularly evident in comparing subjects 1 and 4, who had the same 359 
CAR mutation (A840V), and had markedly different increases in PTH AUC (Figure 3C).   In 360 
fact, while the NPSP795 AUC in subject 1 was generally lower than subject 4 (Figure 3D), the 361 
PTH AUC in subject 1 was higher than in subject 4.  In addition, subject 3 (E228K mutation) had 362 
almost no response to NPSP795 in terms of PTH AUC (Figure 3E), and was considered a non-363 
responder, yet subjects 3 and 5 (E228A mutation) had similar exposure to NPSP795 (Figure 3F).  364 
Baseline PTH and dose of calcium supplementation prior to study entry for each subject was 365 
compared to the respective PTH AUC. There were no statistically significant correlations 366 
between these clinical parameters and PTH AUC as assessed by linear regression analysis. 367 
In vitro analyses. Response by genotype.  To assess potential genotype/phenotype 368 
correlations and understand variability in clinical response to NPSP795, stable cell lines 369 
expressing wild-type (WT) and subject mutant CaRs were generated in HEK293-derived Flp-In-370 
293s cells, and the Ca2+o concentration at which half-maximal (EC50) Ca2+i occurred was 371 
measured.  The same parameter was assessed for an increase in ERK and p38 phosphorylation in 372 
parallel. In addition, the NPSP795 concentration at which these parameters were half-maximally 373 
inhibited (IC50) was determined.  The EC50 for Ca2+i mobilization, and ERK and p38 374 
phosphorylation for all mutant CaRs were significantly less than WT (Table 2).  Likewise, 375 
NPSP795 significantly increased all these parameters (Table 2).  These changes were not 376 
ascribed to differences in total or cell surface expression (Supplemental Figure 4).  Also, 377 
comparable results were obtained in transient and stable transfections (not shown).  Together, 378 
these results suggest that the enhanced signaling responses to Ca2+o, and the ability of calcilytics 379 
to restore such response, were not due to differences in mutant receptor expression.  All EC50 380 
data were compared to the clinical parameter PTH AUC. There were no statistically significant 381 
correlations between any in vitro finding and PTH AUC as assessed by linear regression 382 
analysis.   383 
DISCUSSION 384 
 Hypoparathyroidism, in particular ADH1, is a disease for which there remains a need for 385 
better therapeutics. (10,22,23) Given that ADH1 results from gain-of-function mutations in the CAR, 386 
negative allosteric modulators of the CaR, calcilytics, represent a rational, precision medicine 387 
approach to treating this disease.  Through a public/private partnership between the NIDCR and 388 
NPS Pharmaceuticals (acquired by Shire in 2015), the short-acting calcilytic NPSP795, which 389 
was initially developed as a treatment for osteoporosis, , was repurposed to study the potential 390 
for efficacy in patients with ADH1. In this proof-of-principle, dose-finding study the initial 391 
question was if parathyroid glands in patients with ADH1, which have been essentially dormant 392 
for life, would respond to a calcilytic.  This was clearly shown to be the case.  There were dose-393 
dependent increases in PTH that were significant at the highest drug exposure levels (Figure 3). 394 
The on- and off-effect was rapid, with PTH levels rising rapidly after infusion and dropping 395 
rapidly in a single phase, exponential decay pattern following cessation of drug infusion (Figure 396 
2). At the highest levels of exposure, there appeared to be a decrease in FECa although it did not 397 
reach statistical significance (Figure 2K-L) but was consistent with the predicted effect of a 398 
calcilytic on renal calcium handling, and points to the fact that the study was underpowered to 399 
see a significant effect on FECa.  The short-acting nature of NPSP795 could also account for the 400 
lack of sustained effect on FECa.      401 
 All subjects required both calcitriol and calcium prior to enrolling in the study to 402 
maintain blood calcium levels.  Throughout the study, all subjects were kept on a fixed, 403 
relatively low dose calcium diet (1,000 mg/day), and no subjects were taking calcitriol.  All 404 
subjects received some supplemental calcium at bedtime to avoid symptomatic hypocalcemia 405 
while fasting, and two subjects required a rescue calcium for symptoms of hypocalcemia 406 
(Supplemental Table 2).  The maintenance of blood calcium levels (Figure 2M-O) with 407 
significantly decreased medication would be very unusual in patients with treatment-dependent 408 
ADH1 such as those studied and is consistent with an effect of study drug at maintaining blood 409 
calcium. However, it is likely the case that substantially higher doses of NPSP795 will be needed 410 
to have significant effects on FECa and blood calcium.  It was previously shown in a single-dose 411 
study of PTH 1-84 in patients with hypoparathyroidism that blood levels of PTH near 200 pg/ml, 412 
ten times the levels achieved in this study, were needed to illicit a clear effect on FECa and blood 413 
calcium(24).     414 
 Of note was the marked variability in response to NPSP795 in terms of effects on PTH 415 
that was not explained by differences in drug levels.  The differences in PTH response to 416 
NPS795 were particularly striking in the two patients with the same mutation (subjects 1 and 4, 417 
first-degree cousins) (Figure 3C). Probably some of the difference in PTH response between the 418 
two subjects can be explained by differences in drug levels (Figure 3D), but it is likely most of 419 
the difference is explained by other factors such as metabolism, body mass, diet, sex hormones, 420 
renal function, etc.  In addition, there was no relationship between PTH AUC and NPSP795 drug 421 
levels (Figure 3).  These differences in response, especially between the first-degree cousins, 422 
suggest that there are additional factors that control PTH secretion, such as disease-modifying 423 
genes, that are not well understood and require further investigation.   424 
 This study is limited by the lack of a placebo or control group and a small number of 425 
subjects that represented only 4 CaR mutations.  Although the urinary FECa results suggested a 426 
decrease with exposure to NPSP795, this did not reach statistical significance, which may have 427 
been achieved with a larger number of subjects and a control group.  In addition, referral bias 428 
may affect our findings.  As a tertiary referral center, these subjects may be more severely 429 
affected which could diminish potential generalizability of the findings.  430 
 While this proof-of-principle study was unable to demonstrate significant effects on 431 
urinary FECa and blood calcium due to the small number of subjects and limited drug exposure, 432 
it clearly demonstrated that calcilytics can rapidly stimulate PTH secretion in ADH1 and that it is 433 
highly likely that with adequate drug exposure calcilytics may be an effective treatment for 434 
ADH1.  Further, they may represent a treatment for other forms of hypoparathyroidism, 435 
including ADH2, due to their independent actions on the kidney, and possibly even idiopathic 436 
hypercalciuria.   437 
 438 
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 528 
Figure 1.  NPSP795 Clinical Study Design.  After an initial outpatient screening visit, subjects 529 
were admitted to the National Institutes of Health (NIH) Clinical Center.  An i.v. dose of 5 530 
mg/10min NPSP795 was administered on day 1, and subjects underwent serial sampling for 531 
pharmacokinetic/pharmacodynamic parameters.  If subjects had an increase in ionized calcium to 532 
the normal range or an increase in intact parathyroid hormone (iPTH) to greater than the upper 533 
limit of normal (ULN), the same dose of NPSP795 would be administered on day 2.  If subjects 534 
did not meet the ionized calcium or iPTH parameters, 15 mg/3.5h NPSP795 would be 535 
administered on day 2 along with serial sampling.  The same criteria were used to determine the 536 
dose of NPSP795 on day 3.  Subjects were discharged home on day 4.   537 
 538 
Figure 2. Pharmacokinetic and pharmacodynamic effects of NPSP795.  NPSP795 539 
concentrations significantly increased after infusion as predicted from modeling studies (A-C) 540 
and resulted in a rapid and concentration-dependent increase in % change in PTH (D-F) and PTH 541 
(G-I).   Significant effects on PTH were seen at the highest concentrations in NPSP795 during 542 
the 5 mg bolus infusion on day 1 (D) and with the 30 mg infusion on day 3 (F, I).  The fractional 543 
excretion of calcium (FECa) (J-L) decreased by > 30% following the 15 mg/3.5h, and >40% 30 544 
mg/3.5h doses but did not reach statistical significance.  The ionized calcium levels (M-O) 545 
remained stable during NPSP795 infusions despite fasting and calcium and calcitriol doses being 546 
withheld.  Statistical analysis was performed using mixed model repeat measures analysis.   547 
 548 
Figure 3.  Clinical response to NPSP795 by CaR genotypes.  PTH area under the curve (AUC) 549 
varied widely across the different CAR mutations despite overall similar exposure to NPSP795 550 
(B). The subject with E228K mutation in the CAR had little to no response to NPSP795 (A).  551 
Subjects 1 and 4 were first-degree cousins with the same A840V CAR mutation but had widely 552 
different responses to NPSP795 (C). Differences in response were not accounted for by 553 
differences in NPSP795 clearance, as subject 4 had higher NPSP795 exposure (D), but less of a 554 
response.  Of note, subjects 3 and 5 both had E228 mutations, K and A, respectively, but 555 
markedly different responses. Subject 3 had little response (E), but robust NPSP795 blood levels 556 
(F). 557 
Table 1.  Subject baseline demographics, biochemical profile, and disease characteristics.  558 
 559 
 560 
Subject 
# 
Age Sex Ethnicity CaR 
Mutation 
Ca 
(8.6-10.2 
mg/dL) 
Phos 
(2.5-4.5 
mg/dL) 
iPTH 
(15-65 
pg/mL) 
Cr 
(0.67-1.17 
mg/dL) 
eGFR 
(90 
mL/min/1.73m2) 
FECa Renal 
Ultrasound 
1 55 M Caucasian A840V 7.5 3.6 13.4 1.17 70 0.04 Normal 
2 46 M Caucasian Q245R 7.1 3.3 9.5 1.13 78 0.03 NC/NL 
3 23 F Caucasian E228K 7.6 5.6 5.0 1.43 51 0.04 NC 
4 51 F Caucasian A840V 8 5.6 12.4 1.03 62 0.01 NC 
5 24 M Caucasian E228A 8.5 4.3 6.9 1.05 99 0.01 Normal 
Non-fasting laboratory studies obtained during screening visit while on treatment with calcium and calcitriol. 

First degree cousins. 

Novel mutation.  CaR = 
Calcium sensing receptor; Phos = phosphorus; iPTH = intact parathyroid hormone; Cr = creatinine; eGFR = estimated glomerular filtrate rate; FECa = fractional 
excretion of calcium; NC = nephrocalcinosis; NL = nephrolithiasis 
Table 2.  Summary of in vitro and PTH AUC findings.  561 
 562 
 563 
 
EC50 
Ca2+i 
mobilization 
(mM) 
EC50 
ERK 
phosphorylation 
(mM) 
EC50 
P38MAPK 
phosphorylation 
(mM) 
IC50 
NPSP795 
Ca2+i 
mobilization 
(µM) 
IC50 
NPSP795 
ERK 
phosphorylation 
(nM) 
IC50 
NPSP795 
P38MAPK 
phosphorylation 
(nM) 
Day 3 
PTH 
AUC 
WT 
2.9 3.0 4.2 5.2 112 88  
Q245R 
1.0 2.0 2.0 1.76 52 58 35040 
E228K 
0.8 1.7 1.6 0.04 91 69 1937 
E228A 
0.7 2.1 2.2 1.25 32 10 29280 
A840V 
1.3 2.0 2.3 1.15 50 70 
Subject 1: 
26648 
Subject 4: 9141 
EC
50
 = half-maximal activation; Ca
2+
i
 = intracellular calcium; IC
50
 = half-maximal inhibition;
 
PTH AUC = parathyroid hormone area under the curve
 
  
